216 related articles for article (PubMed ID: 30244272)
1. The role of formation of pyrrole-ATP synthase subunit beta adduct in pyrrolizidine alkaloid-induced hepatotoxicity.
Lu Y; Ma J; Song Z; Ye Y; Fu PP; Lin G
Arch Toxicol; 2018 Nov; 92(11):3403-3414. PubMed ID: 30244272
[TBL] [Abstract][Full Text] [Related]
2. Pyrrolizidine Alkaloid-Induced Hepatotoxicity Associated with the Formation of Reactive Metabolite-Derived Pyrrole-Protein Adducts.
Ma J; Li M; Li N; Chan WY; Lin G
Toxins (Basel); 2021 Oct; 13(10):. PubMed ID: 34679016
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxicity of pyrrolizidine alkaloid in human hepatic parenchymal and sinusoidal endothelial cells: Firm evidence for the reactive metabolites mediated pyrrolizidine alkaloid-induced hepatotoxicity.
Yang M; Ruan J; Fu PP; Lin G
Chem Biol Interact; 2016 Jan; 243():119-26. PubMed ID: 26365561
[TBL] [Abstract][Full Text] [Related]
4. Pyrrole-protein adducts - A biomarker of pyrrolizidine alkaloid-induced hepatotoxicity.
Ma J; Xia Q; Fu PP; Lin G
J Food Drug Anal; 2018 Jul; 26(3):965-972. PubMed ID: 29976414
[TBL] [Abstract][Full Text] [Related]
5. Correlation Investigation between Pyrrole-DNA and Pyrrole-Protein Adducts in Male ICR Mice Exposed to Retrorsine, a Hepatotoxic Pyrrolizidine Alkaloid.
Zhu L; Xue J; He Y; Xia Q; Fu PP; Lin G
Toxins (Basel); 2022 May; 14(6):. PubMed ID: 35737038
[TBL] [Abstract][Full Text] [Related]
6. First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans.
Yang M; Ruan J; Gao H; Li N; Ma J; Xue J; Ye Y; Fu PP; Wang J; Lin G
Arch Toxicol; 2017 Dec; 91(12):3913-3925. PubMed ID: 28620673
[TBL] [Abstract][Full Text] [Related]
7. Developing urinary pyrrole-amino acid adducts as non-invasive biomarkers for identifying pyrrolizidine alkaloids-induced liver injury in human.
Zhu L; Zhang C; Zhang W; Xia Q; Ma J; He X; He Y; Fu PP; Jia W; Zhuge Y; Lin G
Arch Toxicol; 2021 Oct; 95(10):3191-3204. PubMed ID: 34390356
[TBL] [Abstract][Full Text] [Related]
8. Development of a two-layer transwell co-culture model for the in vitro investigation of pyrrolizidine alkaloid-induced hepatic sinusoidal damage.
Lu Y; Ma J; Lin G
Food Chem Toxicol; 2019 Jul; 129():391-398. PubMed ID: 31054999
[TBL] [Abstract][Full Text] [Related]
9. Intestinal and hepatic biotransformation of pyrrolizidine alkaloid N-oxides to toxic pyrrolizidine alkaloids.
Yang M; Ma J; Ruan J; Ye Y; Fu PP; Lin G
Arch Toxicol; 2019 Aug; 93(8):2197-2209. PubMed ID: 31222523
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary toxicity is a common phenomenon of toxic pyrrolizidine alkaloids.
Song Z; He Y; Ma J; Fu PP; Lin G
J Environ Sci Health C Toxicol Carcinog; 2020; 38(2):124-140. PubMed ID: 32500835
[TBL] [Abstract][Full Text] [Related]
11. Fasting augments pyrrolizidine alkaloid-induced hepatotoxicity.
Ma J; Zhang C; He Y; Chen X; Lin G
Arch Toxicol; 2022 Feb; 96(2):639-651. PubMed ID: 34792613
[TBL] [Abstract][Full Text] [Related]
12. Immunoassay approach for diagnosis of exposure to pyrrolizidine alkaloids.
Li N; Zhang F; Lian W; Wang H; Zheng J; Lin G
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2017 Jul; 35(3):127-139. PubMed ID: 28506107
[TBL] [Abstract][Full Text] [Related]
13. Proteomic study of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome in rats.
Li YH; Tai WC; Xue JY; Wong WY; Lu C; Ruan JQ; Li N; Wan TF; Chan WY; Hsiao WL; Lin G
Chem Res Toxicol; 2015 Sep; 28(9):1715-27. PubMed ID: 26280871
[TBL] [Abstract][Full Text] [Related]
14. The toxicokinetic and metabolism of structurally diverse pyrrolizidine alkaloids in rats.
To YC; Pan Y; Yan X; He Y; Lin G
J Ethnopharmacol; 2024 Mar; 321():117390. PubMed ID: 37956911
[TBL] [Abstract][Full Text] [Related]
15. The comparative metabolism of the four pyrrolizidine alkaloids, seneciphylline, retrorsine, monocrotaline, and trichodesmine in the isolated, perfused rat liver.
Yan CC; Cooper RA; Huxtable RJ
Toxicol Appl Pharmacol; 1995 Aug; 133(2):277-84. PubMed ID: 7645024
[TBL] [Abstract][Full Text] [Related]
16. Metabolic activation of the tumorigenic pyrrolizidine alkaloid, retrorsine, leading to DNA adduct formation in vivo.
Wang YP; Fu PP; Chou MW
Int J Environ Res Public Health; 2005 Apr; 2(1):74-9. PubMed ID: 16705803
[TBL] [Abstract][Full Text] [Related]
17. Clinical application of pyrrole-hemoglobin adducts as a biomarker of pyrrolizidine alkaloid exposure in humans.
Ma J; Zhang W; He Y; Zhu L; Zhang C; Liu J; Ye Y; Zhuge Y; Lin G
Arch Toxicol; 2021 Feb; 95(2):759-765. PubMed ID: 33210216
[TBL] [Abstract][Full Text] [Related]
18. 7-Glutathione-pyrrole and 7-cysteine-pyrrole are potential carcinogenic metabolites of pyrrolizidine alkaloids.
He X; Xia Q; Fu PP
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2017 Apr; 35(2):69-83. PubMed ID: 28418776
[TBL] [Abstract][Full Text] [Related]
19. The toxic effects in rats of some synthanecine carbamate and phosphate esters analogous to hepatotoxic pyrrolizidine alkaloids.
Driver HE; Mattocks AR
Chem Biol Interact; 1984 Sep; 51(2):201-18. PubMed ID: 6467455
[TBL] [Abstract][Full Text] [Related]
20. Effects of glutathione and cysteine on pyrrolizidine alkaloid-induced hepatotoxicity and DNA adduct formation in rat primary hepatocytes.
He X; Xia Q; Shi Q; Fu PP
J Environ Sci Health C Toxicol Carcinog; 2020; 38(2):109-123. PubMed ID: 32500832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
